Deep learning of pharmacogenomics resources: moving towards precision oncology
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its responses to drugs. This field, called pharmacogenomics, is a key area in the development of precision oncology. Deep learning (DL) methodology has emerged as a powerful technique to characterize and learn from rapidly accumulating pharmacogenomics data. We introduce the fundamentals and typical model architectures of DL. We review the use of DL in classification of cancers and cancer subtypes (diagnosis and treatment stratification of patients), prediction of drug response and drug synergy for individual tumors (treatment prioritization for a patient), drug repositioning and discovery and the study of mechanism/mode of action of treatments. For each topic, we summarize current genomics and pharmacogenomics data resources such as pan-cancer genomics data for cancer cell lines (CCLs) and tumors, and systematic pharmacologic screens of CCLs. By revisiting the published literature, including our in-house analyses, we demonstrate the unprecedented capability of DL enabled by rapid accumulation of data resources to decipher complex drug response patterns, thus potentially improving cancer medicine. Overall, this review provides an in-depth summary of state-of-the-art DL methods and up-to-date pharmacogenomics resources and future opportunities and challenges to realize the goal of precision oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Davies, D. L., & Bouldin, D. W. (1979) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.1979.4766909 · Cited by 9,145
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 1×
“For efficiently processing chemical information, Simplified Molecular Input Line Entry System (SMILES) [79] encodes molecular graphs of compounds into a human-readable line notation of short ASCII (American Standard Code for Information Interchange) strings.”
MethodMolecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436 · cited 2×
“A proof-of-concept study trained an AAE model using NCI-60 data of the MCF7 cell line and identified potential anti-cancer drugs by screening ∼ 72 million compounds of the PubChem [80–83].”
MethodDeep Inside Convolutional Networks: Visualising Image Classification Models and Saliency Maps
Simonyan, K., Vedaldi, A., & Zisserman, A. (2013) · arXiv · doi:10.48550/arxiv.1312.6034 · Cited by 5,370
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
MoleculeNet: a benchmark for molecular machine learning
Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., Leswing, K., & Pande, V. (2018) · Chemical Science · doi:10.1039/c7sc02664a · Cited by 3,107
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Deep learning for healthcare: review, opportunities and challenges
Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbx044 · Cited by 3,076
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning
Alipanahi, B., Delong, A., Weirauch, M. T., & Frey, B. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3300 · Cited by 2,873
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
An integrated map of structural variation in 2,504 human genomes
Sudmant, P. H., Rausch, T., Gardner, E. J., Handsaker, R. E., Abyzov, A., Huddleston, J., Zhang, Y., Ye, K., Jun, G., Hsi-Yang Fritz, M., et al. (2015) · Nature · doi:10.1038/nature15394 · Cited by 2,354
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Katzman, J. L., Shaham, U., Cloninger, A., Bates, J., Jiang, T., & Kluger, Y. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0482-1 · Cited by 1,995
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Self-citationDeep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“[112] [113].”
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Deep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473 · cited 1×
“In medical informatics and bioinformatics researches, CNNs have been applied to computer-aided diagnosis and sequence-based analysis, such as motif discovery and variant analysis, as reviewed in [38–40].”
MethodPrioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Evaluating the Visualization of What a Deep Neural Network Has Learned
Samek, W., Binder, A., Montavon, G., Lapuschkin, S., & Muller, K.-R. (2017) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2016.2599820 · Cited by 1,164
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
Predicting cancer outcomes from histology and genomics using convolutional networks
Mobadersany, P., Yousefi, S., Amgad, M., Gutman, D. A., Barnholtz-Sloan, J. S., Velázquez Vega, J. E., Brat, D. J., & Cooper, L. A. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717139115 · Cited by 1,084
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901 · cited 1×
“For childhood cancers, the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project has so far comprehensively profiled ∼ 1700 pediatric tumors (including leukemia,Wilms tumor,neuroblastoma and osteosarcoma) [44].”
BackgroundThe Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Hutter, C., & Zenklusen, J. C. (2018) · Cell · doi:10.1016/j.cell.2018.03.042 · Cited by 871
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863 · cited 1×
“In addition, a group at the University of Michigan Comprehensive Cancer Center sequenced tumor samples from 500 adult patients with 30 types of cancers who had metastases in 22 different organs (the MET500 cohort) [43].”
BackgroundHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Massive mining of publicly available RNA-seq data from human and mouse
Lachmann, A., Torre, D., Keenan, A. B., Jagodnik, K. M., Lee, H. J., Wang, L., Silverstein, M. C., & Ma’ayan, A. (2018) · Nature Communications · doi:10.1038/s41467-018-03751-6 · Cited by 701 · cited 1×
“These resources range from characterization of CCLs, primary and metastatic tumors to probing cellular vulnerabilities of CCLs, creating a diverse portfolio for integrative analyses [16–18].”
BackgroundClinical assessment incorporating a personal genome
Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., Dudley, J. T., Ormond, K. E., Pavlovic, A., Morgan, A. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60452-7 · Cited by 674
Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00346 · Cited by 587 · cited 1×
“Besides RNNs, a class of AEs that can generate new samples by learning the distribution of data, namely adversarial AEs (AAEs), has been adopted for de novo drug design [82, 111].”
MethodGillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477 · cited 1×
“…of CCLs resembles genomic or pathway alterations found in primary tumors [15,61, 133–135], it has long been questioned whether in vitro models fully recapitulate primary tumors’ heterogeneity and microenvironment for clinically relevant drug response prediction and drug discovery [136–138].”
BackgroundUsing deep learning to model the hierarchical structure and function of a cell
Ma, J., Yu, M. K., Fong, S., Ono, K., Sage, E., Demchak, B., Sharan, R., & Ideker, T. (2018) · Nature Methods · doi:10.1038/nmeth.4627 · Cited by 435
Cancer Cell Lines for Drug Discovery and Development
Wilding, J. L., & Bodmer, W. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2971 · Cited by 432 · cited 1×
“…of CCLs resembles genomic or pathway alterations found in primary tumors [15,61, 133–135], it has long been questioned whether in vitro models fully recapitulate primary tumors’ heterogeneity and microenvironment for clinically relevant drug response prediction and drug discovery [136–138].”
BackgroundPharmacogenomic agreement between two cancer cell line data sets
The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418
Application of Generative Autoencoder in De Novo Molecular Design
Blaschke, T., Olivecrona, M., Engkvist, O., Bajorath, J., & Chen, H. (2018) · Molecular Informatics · doi:10.1002/minf.201700123 · Cited by 411
Self-citationAn unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
A genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, F., Lu, W., Liu, C., Fang, J., Hou, Y., Handy, D. E., Wang, R., Zhao, Y., Yang, Y., Huang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10744-6 · Cited by 215
Deep learning in pharmacogenomics: from gene regulation to patient stratification
Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., Najarian, K., & Athey, B. D. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0008 · Cited by 207
Using neural networks for reducing the dimensions of single-cell RNA-Seq data
Lin, C., Jain, S., Kim, H., & Bar-Joseph, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx681 · Cited by 197 · cited 2×
“In genomics, AEs have been successfully used to cluster single-cell RNA-seq data that typically include up to 10 000 samples [24, 25].”
MethodGeppert, H., Horváth, T., Gärtner, T., Wrobel, S., & Bajorath, J. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700461s · Cited by 63
Schwessinger, R., Suciu, M. C., McGowan, S. J., Telenius, J., Taylor, S., Higgs, D. R., & Hughes, J. R. (2017) · Genome Research · doi:10.1101/gr.220202.117 · Cited by 35
DeepCOP: deep learning-based approach to predict gene regulating effects of small molecules
Woo, G., Fernandez, M., Hsing, M., Lack, N. A., Cavga, A. D., & Cherkasov, A. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz645 · Cited by 32
Cited by
Deep learning in cancer diagnosis, prognosis and treatment selection
Tran, K. A., Kondrashova, O., Bradley, A., Williams, E. D., Pearson, J. V., & Waddell, N. (2021) · Genome Medicine · doi:10.1186/s13073-021-00968-x · Cited by 932
Machine learning in healthcare
Habehh, H., & Gohel, S. (2021) · Current Genomics · doi:10.2174/1389202922666210705124359 · Cited by 544
Chakraborty, C., Bhattacharya, M., Pal, S., & Lee, S.-S. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100164 · Cited by 274
Convolutional neural network models for cancer type prediction based on gene expression
Mostavi, M., Chiu, Y.-C., Huang, Y., & Chen, Y. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0677-2 · Cited by 264
Self-citationManyazewal, T., Woldeamanuel, Y., Blumberg, H. M., Fekadu, A., & Marconi, V. C. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00487-4 · Cited by 177
Metadata
- Authors
- Chiu, Y.-C., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-08
- Volume
- 21
- Issue
- 6
- Pages
- 2066-2083
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W2996474037
- Cited by
- 78
- References
- 50
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.